Kanghua Biological has released its 2026 interim report, with net profit attributable to the parent company of 141 million yuan. The company's total operating revenue was 538 million yuan, and net cash inflow from operating activities was 161 million yuan. The latest asset-liability ratio was 8.99 percent, up 0.24 percentage points from the previous quarter. Gross margin was 89.76 percent, down 1.21 percentage points from the previous quarter and down 3.02 percentage points from the same period last year. Diluted earnings per share were 1.09 yuan, and the latest return on equity was 3.91 percent.
Chengdu Kanghua Biological ProductsCompany released interim report with net profit of 141 million yuan, indicating financial performance.